Table 1.
General features of immune-checkpoint induced myopathy groups resulting from unsupervised clustering (ICI-DM, ICI-MYO1, ICI-MYO2).
| Characteristic | Overall, N = 351 | ICI-DM, N = 31 | ICI-MYO1, N = 241 | CI-MYO2, N = 81 | p-value2 |
|---|---|---|---|---|---|
|
| |||||
| Female | 11 (31%) | 1 (33%) | 8 (33%) | 2 (25%) | >0.9 |
| Age at biopsy | 67 (60, 74) | 73 (58, 74) | 64 (60, 72) | 69 (67, 72) | 0.6 |
| Dermatomyositis | 3 (8.6%) | 3 (100%) | 0 (0%) | 0 (0%) | <0.001 |
| Inflammatory infiltrates | 25 (71%) | 3 (100%) | 19 (79%) | 3 (38%) | 0.056 |
| Treatment cycle | >0.9 | ||||
| 1 | 16 (46%) | 1 (33%) | 11 (46%) | 4 (50%) | |
| 2 | 13 (37%) | 2 (67%) | 8 (33%) | 3 (38%) | |
| 3 | 5 (14%) | 0 (0%) | 4 (17%) | 1 (12%) | |
| 4 | 1 (2.9%) | 0 (0%) | 1 (4.2%) | 0 (0%) | |
| PD1 inhibitor | 24 (69%) | 2 (67%) | 14 (58%) | 8 (100%) | 0.065 |
| PD-L1 inhibitor | 11 (31%) | 1 (33%) | 10 (42%) | 0 (0%) | 0.065 |
| CTLA4 inhibitor | 5 (14%) | 0 (0%) | 2 (8.3%) | 3 (38%) | 0.11 |
| Myocarditis | 13 (37%) | 0 (0%) | 13 (54%) | 0 (0%) | 0.006 |
| Diplopia | 7 (20%) | 0 (0%) | 6 (25%) | 1 (12%) | 0.8 |
| Dysphagia | 4 (11%) | 0 (0%) | 2 (8.3%) | 2 (25%) | 0.5 |
| Anti-striational | 15 (43%) | 0 (0%) | 11 (46%) | 4 (50%) | 0.6 |
| Anti-AChR | 14 (40%) | 0 (0%) | 12 (50%) | 2 (25%) | 0.010 |
| Other myositis autoantibodies | 16 (46%) | 3 (100%) | 12 (50%) | 1 (12%) | 0.051 |
| CK at biopsy | 652 (219, 1,218) | 428 (278, 4,758) | 896 (278, 1,394) | 427 (62, 830) | 0.3 |
| Peak CK | 1,184 (462, 6,118) | 428 (278, 4,758) | 1,240 (899, 6,565) | 652 (379, 4,771) | 0.4 |
1
n (%); Median (IQR)
2
Fisher’s exact test; Kruskal-Wallis rank sum test